Last updated on October 2018

Relaxin in Multiple Sclerosis (MS)


Brief description of study

This study will evaluate relaxin (RLX) and Semaphorin 4A (Sema4A) levels in patients with multiple sclerosis.

Detailed Study Description

The goal of this study is to obtain baseline information on serum and cerebrospinal fluid (CSF) relaxin and Sema4A levels in patients with MS, as well as to further study RXFP-1 receptor binding affinity for RLX in patients with active and clinically stable MS, and further characterize the role of Sema4A in MS patients.

Clinical Study Identifier: NCT01909492

Find a site near you

Start Over

Providence MS Center

Portland, OR United States
  Connect »